## Contents

### BREAKING ADVANCES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1035</td>
<td>Highlights from Recent Cancer Literature</td>
</tr>
</tbody>
</table>

### REVIEW

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1037</td>
<td>Heterogeneity of Neoplastic Stem Cells: Theoretical, Functional, and Clinical Implications</td>
</tr>
</tbody>
</table>

### MEETING REPORT

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1046</td>
<td>Twenty-fourth Annual Pezcoller Symposium: Molecular Basis for Resistance to Targeted Agents</td>
</tr>
</tbody>
</table>

### PRIORITY REPORTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1050</td>
<td>Clonal Progression of Prostate Cancers from Gleason Grade 3 to Grade 4</td>
</tr>
<tr>
<td>1056</td>
<td>Unconventional Role of the Inwardly Rectifying Potassium Channel Kir2.2 as a Constitutive Activator of RelA in Cancer</td>
</tr>
</tbody>
</table>

### CLINICAL STUDIES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1063</td>
<td>Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients</td>
</tr>
</tbody>
</table>

### INTEGRATED SYSTEMS AND TECHNOLOGIES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1076</td>
<td>Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms</td>
</tr>
<tr>
<td>1086</td>
<td>Impact of Tumor Progression on Cancer Incidence Curves</td>
</tr>
</tbody>
</table>

---

**Note:** The above content is a snapshot of the table of contents from a cancer research journal. Each entry provides a brief overview of the research topics covered in the respective sections.
ENDOCAN IS UPREGULATED ON TUMOR VESSELS IN INVASIVE BLADDER CANCER WHERE IT MEDIATES VEGF-A–INDUCED ANGIogenesis
Filip Roudnicky, Cedric Poyet, Peter Wild, Sarah Krampitz, Fabrizia Negrini, Reto Huggenberger, Anja Bogler, Robert Stöhr, Arndt Hartmann, Maurizio Provenzano, Vivianne I. Otto, and Michael Detmar

**Précis:** A more tumor-selective approach to disrupt VEGF signaling is revealed as a strategy for antiangiogenic cancer therapy, focusing on a molecule that mediates VEGF action but is expressed selectively only in the tumor vasculature.

TARGETING GALECTIN-1 OVERCOMES BREAST CANCER-ASSOCIATED IMMUNOSUPPRESSION AND PREVENTS METASTATIC DISEASE
Tomáš Dalotto-Moreno, Diego O. Croci, Juan P. Cerliani, Verónica C. Martínez-Allo, Sebastián Dergan-Dylo, Santiago P. Méndez-Huergo, Juan C. Stupirski, Daniel Mazal, Eduardo Osinaga, Marta A. Toscano, Victoria Sundblad, Gabriel A. Rabinovich, and Mariana Salatino

**Précis:** Findings offer preclinical genetic validation to block an immunosuppressive lectin commonly expressed in aggressive cancers as a strategy to reverse immune escape and blunt metastatic progression.

INHIBITION OF RAPAMYCIN-INDUCED AKT ACTIVATION ELICITS DIFFERENTIAL ANTITUMOR RESPONSE IN HEAD AND NECK CANCERS

**Précis:** This study reports a functional assay for the mTOR pathway that may be clinically useful for stratifying head and neck cancer patients who are being considered for mTOR pathway targeting therapies.

MOESIN IS A GLIOMA PROGRESSION MARKER THAT INDUCES PROLIFERATION AND WNT/β-CATENIN PATHWAY ACTIVATION VIA INTERACTION WITH CD44
Xiaoping Zhu, Fabiana C. Morales, Nitin Kumar Agarwal, Turgut Dogruluk, Mihai Gagea, and Maria-Magdalena Georgescu

**Précis:** This study reveals how an actin membrane-connecting protein acts as a oncogene to drive the function of an important stem cell molecule in glioblastoma, the most aggressive form of brain cancer, with implications for more effective therapy of this disease.

TRASK LOSS ENHANCES TUMORIGENIC GROWTH BY LIBERATING INTEGRIN SIGNALING AND GROWTH FACTOR RECEPTOR CROSS-TALK IN UNANCHORED CELLS
Danislaw S. Spassov, Ching Hang Wong, Sunny Y. Wong, Jeremy F. Reiter, and Mark M. Moasser

**Précis:** Tumor cell growth is restricted to anchored states of the cell unless there is a loss of function in the cell surface protein Trask, which exerts a tumor-suppressing function that blocks anchorage-independent cell growth.
The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
Tony Gutschner, Monika Hammerle, Moritz Elßmann, Jeff Hsu, Youngsoo Kim, Gene Hung, Alexey Revenko, Gayatri Arun, Marion Stentrup, Matthias Groß, Martin Zörnig, A. Robert MacLeod, David L. Spector, and Sven Diederich

Précis: Findings identify a long noncoding RNA with fundamental importance in lung cancer metastasis and potential therapeutic application in metastasis prevention.

TUMOR AND STEM CELL BIOLOGY

MYC Regulation of CHK1 and CHK2 Promotes Radioresistance in a Stem Cell-like Population of Nasopharyngeal Carcinoma Cells
Wen-Jun Wang, Si-Pei Wu, Jia-Bin Liu, Yong-Sheng Shi, Xue Huang, Qian-Bing Zhang, and Kai-Tai Yao

Précis: Targeting an important DNA-damage-checkpoint signaling axis with an important role in stem cells may offer an especially robust therapeutic strategy to reverse stem cell radioresistance.

Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression
Pei-Chun Lin, Ya-Lin Chiu, Samprit Banerjee, Kyung Park, Juan Miguel Mosquera, Eugenia Giannopoulou, Pedro Alves, Ashutosh K. Tewari, Mark B. Gerstein, Himisha Beltran, Ari M. Melnick, Olivier Elemento, Francesca Demichelis, and Mark A. Rubin

Précis: This study identifies a novel biomarker for prostate cancer progression and introduces a new mechanistic concept associated with AR regulation of cell cycle progression.

Tumor Suppressor Function of the Plasma Glutathione Peroxidase Gpx3 in Colitis-Associated Carcinoma

Précis: Results suggest an immunomodulatory role for an extracellular glutathione peroxidase that acts to limit the development of colitis-associated colon carcinoma.

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

Trastuzumab-Resistant Cells Rely on a HER2-PtK-FoxO-Survivin Axis and Are Sensitive to PtK Inhibitors
Anindita Chakrabarty, Neil E. Bhola, Cammie Sutton, Ritwik Ghosh, María Gabriela Kuba, Bhuvanesh Dave, Jenny C. Chang, and Carlos L. Arteaga

Précis: This study reveals how PtK inhibitors can reverse resistance to Herceptin in breast cancer cells, an important clinical challenge.

CCR2 Deficiency Prevents Neuronal Dysfunction and Cognitive Impairments Induced by Cranial Irradiation
Karim Belarbi, Timothy Jopson, Carla Arellano, John R. Fike, and Susanna Rosi

Précis: Radiation-induced cognitive impairments in patients may be ameliorated by targeting CCR2 signaling, a rather surprising result, suggesting that strategies to limit proinflammatory myeloid cell responses may reduce this important side effect of cranial radiotherapy for brain tumors or metastases.

Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer through Loss of ABCA1
Byron H. Lee, Margaret G. Taylor, Peggy Robinet, Jonathan D. Smith, Jessica Schweitzer, Ephraim Sehayek, Sara M. Fazzaroni, Cristina Magi-Galluzzi, Eric A. Klein, and Angela H. Ting

Précis: A key cholesterol efflux transporter is hypermethylated in late stage prostate cancer, leading to higher levels of intracellular cholesterol and potentiation of tumor progression.
ABOUT THE COVER

Galectin-1, a carbohydrate-binding protein, abundantly expressed at sites of tumor growth and metastasis, promotes tumor progression by influencing diverse cancer-related events including tumor cell migration, angiogenesis, and tumor-immune escape. Dalotto-Moreno and colleagues show that galectin-1 contributes to immunosuppression during progression of breast cancer. Human breast cancer biopsies expressed substantial amounts of galectin-1, which positively correlated with tumor grade. Silencing Gal1 expression in the 4T1 breast tumor model reduced tumor growth and lung metastases. This effect was accompanied by a diminished frequency and suppressive activity of CD4$^+$CD25$^+$Foxp3$^+$ regulatory T cells in both the tumor and metastatic lungs. For details, see article by Dalotto-Moreno and colleagues on page 1107.
Cancer Research

73 (3)


Updated version  Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/73/3

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.